Gonadorelin

Two things make gonadorelin unusual. First, dosing pattern is everything: delivered in natural-like pulses it stimulates the pituitary, but given continuously it actually shuts the pituitary down (the principle behind GnRH-agonist drugs like leuprolide used in prostate cancer and endometriosis). Second, the original branded products (Factrel for diagnostics, Lutrepulse for fertility) have largely been discontinued in many markets, so most current human use is either niche specialist supply or — increasingly — off-label, compounded product prescribed in men's-health and TRT clinics.

Gonadorelin sits on solid but narrow ground. Its diagnostic use as a GnRH stimulation test is decades old and well characterised in endocrinology practice. Pulsatile gonadorelin for ovulation induction in hypothalamic amenorrhoea is supported by long-standing clinical use and was the basis of regulatory approval for pulsatile products; reviews report ovulation and pregnancy rates comparable to, and with a lower multiple-pregnancy risk than, gonadotropin injections in the right patients (see Cochrane and reproductive-medicine literature). Where the evidence thins out is the use it is now most famous for: maintaining testicular function and fertility in men on testosterone therapy. Here the mechanism is well understood and the analogy to hCG is reasonable, but high-quality randomised trials specific to gonadorelin in this role are sparse, and much of the practical knowledge comes from clinic experience and the longer track record of pulsatile GnRH in male hypogonadotropic hypogonadism rather than from large TRT-adjunct trials. The honest summary: strong, approved-quality evidence for the diagnostic and fertility indications; a plausible but under-evidenced off-label rationale for the TRT use that has driven its current popularity.

For context only — this is not a protocol and not advice. In diagnostic testing, a single dose of gonadorelin is given (intravenously or subcutaneously) and blood LH/FSH are sampled over the following hour. For ovulation induction, historic pulsatile products delivered very small doses (in the microgram range) every 60–90 minutes via a worn pump to imitate the body's natural rhythm. The off-label TRT-adjunct use seen in men's-health clinics involves small subcutaneous doses, but because gonadorelin's half-life is only minutes, dosing frequency and pattern dominate any effect — which is exactly why this should be handled by a clinician, not self-directed. Product labelling for the discontinued branded forms is the reference point where it exists; compounded preparations have no standardised label.

At the low doses used clinically, gonadorelin is generally well tolerated. Reported effects include injection-site reactions, headache, nausea, abdominal or pelvic discomfort, and flushing. Rare hypersensitivity and, very rarely, anaphylactic reactions have been described, particularly with repeated or pump-delivered dosing. Because the drug acts on the reproductive axis, pulsatile use for fertility carries a risk of ovarian overstimulation and multiple pregnancy, so it requires monitoring. A key conceptual safety point: continuous or wrongly timed dosing can paradoxically suppress the very hormones it is meant to stimulate. It should be avoided in pregnancy (outside specialist fertility care), in hormone-sensitive conditions without specialist oversight, and in anyone with a known hypersensitivity. Compounded or research-chemical "gonadorelin" sold outside the licensed supply chain has no guaranteed purity, sterility or dose accuracy, and self-administration removes the clinical monitoring this drug is designed to be used with.